JRSS JRSIS HEALTH CARE Corp
Services-Hospitals · OTC · SEC CIK 1597892 · Fiscal year ends 12/31
Financial factors as of 2024-09-30 (2024Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-100.5%
TTM EPS YoY-100.1%
Revenue 3-yr CAGR-52.4%
Net income 3-yr CAGR—
Margins
Gross margin9.4%
Operating margin-7.0%
Net margin-3.7%
FCF margin—
EBITDA margin-6.4%
Returns
ROE-125.7%
ROA-13.2%
ROIC (approx.)-171.2%
Asset turnover3.58x
Leverage & solvency
Liabilities / assets111.3%
Debt / equity—
Current ratio0.78x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.67x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.46M | $1.72M |
| Cost of revenue | $2.98M | $1.69M |
| Gross profit | $483,051 | $26,211 |
| R&D expense | $189,266 | $283,043 |
| SG&A expense | $336,049 | $283,293 |
| Operating income | -$188,598 | -$684,776 |
| Interest expense | $56,443 | $64,709 |
| Pretax income | -$85,613 | -$673,260 |
| Income tax | $8,975 | — |
| Net income | -$80,912 | -$575,839 |
| EBITDA | -$134,783 | -$649,873 |
| EPS (basic) | -0.00 | -0.01 |
| EPS (diluted) | -0.00 | -0.01 |
| Weighted avg. shares (diluted) | 77.25M | 61.33M |
| Balance sheet | ||
| Cash & equivalents | $118,114 | $158,813 |
| Receivables | $714,658 | $683,452 |
| Inventory | $455,240 | $562,015 |
| Current assets | $1.83M | $1.66M |
| PP&E, net | $50,024 | $62,223 |
| Intangibles | $257,334 | $303,195 |
| Total assets | $2.14M | $2.04M |
| Current liabilities | $2.28M | $2.11M |
| Short-term debt | $18,713 | $49,709 |
| Long-term debt | $24,950 | — |
| Total debt | $43,663 | — |
| Total liabilities | $2.31M | $2.11M |
| Shareholders' equity | -$137,406 | -$58,453 |
| Net debt | -$74,451 | — |
| Shares outstanding | 82.59M | 76.76M |
| Cash flow statement | ||
| Operating cash flow | $516,724 | -$1.76M |
| Capital expenditure | $1,484 | $44,644 |
| Free cash flow | $515,240 | -$1.81M |
| Investing cash flow | $18,885 | -$2.83M |
| Financing cash flow | -$568,365 | $1.86M |
| Depreciation & amortization | $53,815 | $34,903 |
| Stock-based compensation | — | $245,465 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.